Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm and Aurigene Discovery Technologies have entered into an agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.
Subscribe to our email newsletter
Debiopharm said Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours, including resistance to chemotherapy.
Aurigene CEO CSN Murthy said coming as it does after a successful collaboration programme they already had with Debiopharm, and as a continuation of their close to 5 year association, the relationship between Debiopharm and Aurigene demonstrates the strategic fit between organisations with complimentary scientific skills.